Given that a recent study found that targeting of RSPO3 in human tumor xenografts with PTPRK-RSPO3 inhibits tumor growth and promotes differentiation [3], RSPO3 is a candidate for the treatment of colorectal tumors, and DNA analysis that considers only gene-gene fusions is inadequate for identifying the relevant cases. Here, RSPO3 is linked to colorectal neoplasm.